论文部分内容阅读
目的:通过甘精胰岛素联用瑞格列奈与预混人工合成胰岛素(诺和灵30R)治疗初诊2型糖尿病患者的比较,探讨其疗效与安全性。方法:将初诊2型糖尿病患者随机分为甘精胰岛素+瑞格列奈组(A组)和诺和灵30R组(B组),根据血糖情况调整用药剂量。治疗12周后,比较两组的空腹血糖、餐后2小时血糖、糖化血红蛋白(HbA1c)、体重指数(BMI)和低血糖发生率。结果:A组低血糖事件明显少于B组,在餐后2小时血糖方面也优于B组,差异有统计学意义(p<0.05);在空腹血糖、HbA1c和BMI方面差异无统计学意义(p>0.05)。结论:甘精胰岛素与瑞格列奈联用对于初诊2型糖尿病患者,其血糖控制满意,餐后血糖更加平稳,低血糖发生率低,是一种针对初诊2型糖尿病患者安全、有效、方便的治疗方案。
OBJECTIVE: To compare the efficacy of glargine plus repaglinide with premixed synthetic insulin (norepinephrine 30R) in the treatment of newly diagnosed type 2 diabetes mellitus (T2DM) and to investigate its efficacy and safety. Methods: Patients with newly diagnosed type 2 diabetes were randomly divided into insulin glargine + repaglinide group and norepinephrine 30R group (group B). The dosage was adjusted according to the blood glucose level. After 12 weeks of treatment, fasting blood glucose, 2-hour postprandial blood glucose, HbA1c, body mass index (BMI) and incidence of hypoglycemia were compared. Results: The incidence of hypoglycaemia in group A was significantly less than that in group B, and also better than that in group B at 2 hours postprandial blood glucose (p <0.05). There was no significant difference in fasting blood glucose, HbA1c and BMI (p> 0.05). CONCLUSIONS: Combination of glargine and repaglinide is satisfactory for glycometabolism in newly diagnosed type 2 diabetic patients. The postprandial blood glucose is more stable and the incidence of hypoglycemia is lower. It is a safe, effective and convenient method for the newly diagnosed type 2 diabetic patients Treatment program.